Health Care • Biotechnology: Pharmaceutical Preparations
$17.04 ▲ +0.06
(+0.35%)
MKT CAP: $3.18B • VOL: 1.43M
52W L $14 52W H $27
ROARABLE / RQD
D- • 40/100
PIOTROSKI
1 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$14
MEDIAN
$19
MEAN
$19
HIGH
$23
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE DYN TAPE
DYN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $20.62 | $19.60 | 2025-02-14 | $15.51 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $21.47 | $20.11 | 2025-02-06 | $16.02 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $19.43 | $18.74 | 2025-01-29 | $16.36 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $17.38 | — | 2025-01-17 | $16.70 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $15.00 | $16.19 | 2025-01-09 | $15.17 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $20.28 | $17.72 | 2024-12-18 | $14.82 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $16.53 | $17.21 | 2024-12-04 | $15.85 | -4.3% | 48% | C |